Zemplar Injection

  • Secondary hyperparathyroidism or hypocalcemia

Zemplar Injection Generic Name & Formulations

General Description

Paricalcitol 2mcg/mL, 5mcg/mL; soln for IV inj; contains alcohol.

Pharmacological Class

Vit. D analog.

See Also

    How Supplied

    Caps—30; Single-dose vials (2mcg, 5mcg)—25; Multi-dose vials (5mcg)—25


    Generic Availability


    Zemplar Injection Indications


    Secondary hyperparathyroidism due to chronic kidney disease (CKD) on dialysis.

    Zemplar Injection Dosage and Administration


    Give as IV bolus inj during dialysis. Initially 0.04–0.1mcg/kg (2.8–7mcg) no more often than every other day; may increase in increments of 2–4mcg at 2–4 week intervals; max 0.24mcg/kg. Titrate based on iPTH levels (see full labeling).


    <5yrs: not established. Give as IV bolus inj during dialysis. ≥5yrs: iPTH <500pg/mL: initially 0.04mcg/kg 3 times weekly (no more often than every other day). iPTH ≥500pg/mL: initially 0.08mcg/kg 3 times weekly. Titrate based on iPTH levels (see full labeling).

    Zemplar Injection Contraindications


    Vit. D toxicity. Hypercalcemia.

    Zemplar Injection Boxed Warnings

    Not Applicable

    Zemplar Injection Warnings/Precautions


    Risk of hypercalcemia. Monitor serum calcium, phosphorus, and iPTH at least every 2 weeks for 3 months during initiation or after dose adjustments, then monthly for 3 months, then every 3 months thereafter. IV: monitor serum calcium twice weekly and iPTH every 2–4 weeks after initiation or dose adjustment. If hypercalcemia occurs, reduce dose or withhold until normal. Severe hepatic impairment: not studied. Pregnancy. Nursing mothers: not recommended.

    Zemplar Injection Pharmacokinetics

    See Literature

    Zemplar Injection Interactions


    Potentiated by strong CYP3A4 inhibitors (eg, boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole); monitor and dose adjustment may be needed. Caps: cholestyramine or mineral oil may impair absorption; separate dosing by ≥1hr before or 4–6hrs after. Increased risk of hypercalcemia with concomitant calcium-containing products (at high doses), thiazide diuretics, other Vit. D compounds, phosphate; monitor and may need to adjust paricalcitol dose. Caution with concomitant digitalis compounds; increased toxicity. Concomitant aluminum-containing preparations (eg, antacids, phosphate binders); may cause aluminum bone toxicity.

    Zemplar Injection Adverse Reactions

    Adverse Reactions

    Diarrhea, nasopharyngitis, dizziness, vomiting, hypertension, hypersensitivity, nausea, edema; hypercalcemia, hypercalciuria, hyperphosphatemia, suppression of PTH, adynamic bone disease.

    Zemplar Injection Clinical Trials

    See Literature

    Zemplar Injection Note

    Not Applicable

    Zemplar Injection Patient Counseling

    See Literature